New drug approvals for 2020: Synthesis and clinical applications

Shuo Yuan; Yong-Qiang Luo; Jia-Hui Zuo; Hui Liu; Fang Li; Bin Yu

doi:10.1016/j.ejmech.2021.113284

New drug approvals for 2020: Synthesis and clinical applications

Eur J Med Chem. 2021 Apr 5:215:113284. doi: 10.1016/j.ejmech.2021.113284. Epub 2021 Feb 12.

Authors

Shuo Yuan¹, Yong-Qiang Luo¹, Jia-Hui Zuo¹, Hui Liu¹, Fang Li¹, Bin Yu²

Affiliations

¹ School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Military of Education, Zhengzhou University, Zhengzhou, 450001, China.
² School of Pharmaceutical Sciences & Key Laboratory of Advanced Drug Preparation Technologies, Military of Education, Zhengzhou University, Zhengzhou, 450001, China. Electronic address: yubin@zzu.edu.cn.

PMID: 33611190
DOI: 10.1016/j.ejmech.2021.113284

Abstract

53 New drugs including 38 chemical entities and 15 biologics were approved by the U.S. Food and Drug Administration during 2020. Among the marketed drugs, 34 new small molecule drugs and 4 new diagnostic agents with privileged structures and novel clinical applications represent as promising leads for the development of new drugs with the similar indications and improved therapeutic efficacy. This review is mainly focused on the clinical applications and synthetic methods of 34 small-molecule drugs newly approved by the FDA in 2020.

Keywords: Chemical synthesis; Clinical applications; New drugs.

Publication types

Review

MeSH terms

Drug Approval
Humans
Organic Chemicals / chemical synthesis*
Organic Chemicals / therapeutic use*
United States
United States Food and Drug Administration

Substances

Organic Chemicals